Brokerages Set Reviva Pharmaceuticals Holdings, Inc. (NASDAQ:RVPH) PT at $66.67

Reviva Pharmaceuticals Holdings, Inc. (NASDAQ:RVPH) has earned a consensus rating of “Moderate Buy” from the eight research firms that are currently covering the firm, Marketbeat.com reports. One analyst has rated the stock with a sell recommendation, two have assigned a hold recommendation and five have issued a buy recommendation on the company. The average 12 month price objective among analysts that have covered the stock in the last year is $66.6667.

Several research firms recently commented on RVPH. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Reviva Pharmaceuticals in a research report on Tuesday, April 21st. Wall Street Zen upgraded Reviva Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Sunday, July 5th.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently modified their holdings of the company. XTX Topco Ltd grew its holdings in shares of Reviva Pharmaceuticals by 63.6% during the fourth quarter. XTX Topco Ltd now owns 164,291 shares of the company’s stock worth $46,000 after buying an additional 63,893 shares in the last quarter. State Street Corp lifted its stake in Reviva Pharmaceuticals by 202.4% in the 4th quarter. State Street Corp now owns 383,200 shares of the company’s stock valued at $107,000 after acquiring an additional 256,500 shares in the last quarter. Geode Capital Management LLC boosted its position in Reviva Pharmaceuticals by 87.6% during the 4th quarter. Geode Capital Management LLC now owns 1,048,954 shares of the company’s stock worth $293,000 after acquiring an additional 489,711 shares during the last quarter. Millennium Management LLC boosted its position in Reviva Pharmaceuticals by 15.0% during the 3rd quarter. Millennium Management LLC now owns 1,711,221 shares of the company’s stock worth $631,000 after acquiring an additional 223,178 shares during the last quarter. Finally, Lido Advisors LLC bought a new position in shares of Reviva Pharmaceuticals during the 3rd quarter worth approximately $37,000. 63.18% of the stock is owned by institutional investors and hedge funds.

Reviva Pharmaceuticals Stock Performance

Shares of RVPH stock opened at $0.45 on Friday. Reviva Pharmaceuticals has a 52 week low of $0.26 and a 52 week high of $17.20. The company’s 50 day moving average price is $0.57 and its two-hundred day moving average price is $1.85. The company has a market capitalization of $5.90 million, a P/E ratio of -0.11 and a beta of 0.53.

Reviva Pharmaceuticals (NASDAQ:RVPH) last released its quarterly earnings results on Thursday, May 14th. The company reported ($0.46) earnings per share for the quarter, missing the consensus estimate of ($0.36) by ($0.10). Analysts forecast that Reviva Pharmaceuticals will post -2.96 earnings per share for the current year.

Reviva Pharmaceuticals Company Profile

Reviva Pharmaceuticals, Inc (NASDAQ: RVPH) is a specialty pharmaceutical company focused on the acquisition, development and commercialization of prescription drug products in the United States and select international markets. Founded in 2002 and headquartered in Coral Gables, Florida, Reviva targets under-promoted, off-patent pharmaceuticals for which novel dosage forms can enhance patient compliance and therapeutic outcomes.

The company’s core activities include the identification of FDA-approved drug candidates, formulation development to address niche or underserved patient populations—such as pediatric and orphan indications—and supporting regulatory filings.